ReviewDrugs2010
Raltegravir: in treatment-naive patients with HIV-1 infection.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2019Pooled it
- Association of HLA-B*53 With DRESS Syndrome in Patients Treated With Raltegravir: Two Case Reports and a Literature Review.Basic & clinical pharmacology & toxicology · 2025Review
- Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial.AIDS research and therapy · 2022Article
- 4-(1-Benzyl-1Iranian journal of pharmaceutical research : IJPR · 2021Article
- Classification and Design of HIV-1 Integrase Inhibitors Based on Machine Learning.Computational and mathematical methods in medicine · 2021Article
- HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence.Molecules (Basel, Switzerland) · 2018Article
- Review
- 4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.Journal of medicinal chemistry · 2014Article
- Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.Journal of medicinal chemistry · 2014Article
- Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.Paediatric drugs · 2014Review
- Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Antimicrobial agents and chemotherapy · 2012Article
- Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.Chemical biology & drug design · 2012Article
- Article
- Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.Bioorganic & medicinal chemistry letters · 2011Article
- Allosteric inhibitor development targeting HIV-1 integrase.ChemMedChem · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Raltegravir, a first-in-class, oral HIV type-1 (HIV-1) integrase inhibitor, blocks the covalent integration of HIV-1 complementary DNA into the host genome. In a large, randomized, double-blind, multinational, ongoing trial in treatment-naive patients with HIV-1 infection, raltegravir 400 mg twice daily was noninferior to efavirenz 600 mg once daily in achieving plasma HIV-1 RNA viral levels of <50 copies/mL after 48 weeks' treatment (primary endpoint), when used as part of an antiretroviral therapy (ART) combination regimen. The time to achieve a virological response was significantly shorter in the raltegravir group than in the efavirenz group. Furthermore, significantly more raltegravir than efavirenz recipients achieved HIV-1 RNA viral levels of <50 copies/mL at weeks 2-16. The efficacy of raltegravir in achieving HIV-1 RNA levels of <50 copies/mL was also demonstrated in subgroups of patients separated according to baseline viral levels, CD4+ cell counts and viral subtypes. Preliminary evidence suggests that both virological and CD4+ cell count improvements were maintained at 96 weeks for treatment-naive recipients of raltegravir 400 mg twice daily. As part of an ART combination regimen, raltegravir treatment was generally well tolerated and was associated with significantly fewer drug-related adverse events than efavirenz treatment. Moreover, after 96 weeks, raltegravir treatment was associated with a significantly lower impact on serum lipid levels than efavirenz treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.